Abstract 383P
Background
The body mass index (BMI) before therapy shows a variety of progression free survival (PFS), it was said in the BMI study <18.5 kg/m2, had a worse progression free survival, compared to BMI 18.5-24.9 kg/m and BMI >24.9 kg/m2. The neutrophil lymphocyte ratio before therapy showed a variety of progression free survival (PFS). It was said that NLR ≥ 3 patients study have a better progression free survival compared to those < 3, but these results are still contradictory. The aim of this study was to determine body mass index and neutrophil to lymphocyte ratio before therapy to predict 3-year progression free survival in patients with locally advanced nasopharyngeal carcinom.
Methods
Patients with locally advanced nasopharyngeal carcinoma (N=289) from 2015 until 2017 who underwent chemoradiation with and without adjuvant or neoadjuvant chemotherapy were enrolled. Body mass index before therapy was classified as <18.5 (underweight), 18.5-24.9 (normal), and >24.9 (overweight or obese) and the neutrophil to lymphocyte ratio before therapy was categorized as ≥3 and <3, using the Cox proportional hazard and Kaplan-Meier models.
Results
Body mass index 18.5-24.9 and 24.9 on Cox regression has a better 3-year PFS with adjusted hazard ratio (HR = 0.219; CI = 1.43-1.59; p = 0.025 and HR = 0.136 ; CI = 1.51-1.76; p = 0.025 ), BMI <18.5 indicates a lower 3-year PFS (HR=1.644; CI=1.28-1.56; P=0.001). While NLR ≥3 before therapy had a better 3-year PFS (HR=0.152; CI 1.37-1.53, p=0.001) than NLR <3 (HR=1.603; CI 1.52-1.69, p=0.013.
Conclusions
Patients with BMI<18.5 before therapy had a lower 3-year PFS, and BMI>24.9 had a 3-year higher PFS than the normal weight group and NLR ≥3 had a higher PFS than under 3. This study provides a good understanding better between BMI and PFS and NLR and PFS, but further research is needed to confirm the result in different populations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
183P - Final analysis of phase II clinical study evaluating the safety and effectiveness of neoadjuvant S-1 + oxaliplatin combination therapy for older patients with locally advanced gastric cancer
Presenter: Eiji Oki
Session: Poster Display
Resources:
Abstract
184P - Neutropenia as a predictive and prognostic factor in nanoliposomal-irinotecan/fluorouracil/leucovorin therapy for pancreatic cancer: Findings from the NAPOLEON-2 study (NN-2301)
Presenter: Yuki Sonoda
Session: Poster Display
Resources:
Abstract
185P - Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A real-world, multicenter study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract
186P - Efficacy and safety of fruquintinib with nab-paclitaxel in advanced G/GEJ cancer after exposure to immune checkpoint inhibitors: A single-center prospective clinical trial
Presenter: Xiaoting Ma
Session: Poster Display
Resources:
Abstract
187P - Neoadjuvant cadonilimab (PD-1/CTLA-4 bispecific antibody) plus transhepatic arterial infusion chemotherapy (HAIC) for resectable multinodular CNLC Ib/IIa hepatocellular carcinoma (Car-Hero)
Presenter: Yongguang Wei
Session: Poster Display
Resources:
Abstract
188P - Impact of metformin, statin, aspirin and insulin on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Margherita Rimini
Session: Poster Display
Resources:
Abstract
189P - Safety run-in results from LEAP-014: First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Shun Yamamoto
Session: Poster Display
Resources:
Abstract
190P - Perioperative camrelizumab combined with chemotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: A single-arm, single-center, phase II clinical trial
Presenter: Jiaxing He
Session: Poster Display
Resources:
Abstract
191P - Predictive value of CXCR6 expression in gastric cancer survival and immune modulation
Presenter: Song-Hee han
Session: Poster Display
Resources:
Abstract
192P - Antiangiogenesis-related adverse events (ARAE) to predict efficacy in patients with advanced gastric cancer (AGC) treated with apatinib + chemotherapy: Results from two prospective studies
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract